381 related articles for article (PubMed ID: 19232896)
1. Bivalirudin and clopidogrel with and without eptifibatide for elective stenting: effects on platelet function, thrombelastographic indexes, and their relation to periprocedural infarction results of the CLEAR PLATELETS-2 (Clopidogrel with Eptifibatide to Arrest the Reactivity of Platelets) study.
Gurbel PA; Bliden KP; Saucedo JF; Suarez TA; DiChiara J; Antonino MJ; Mahla E; Singla A; Herzog WR; Bassi AK; Hennebry TA; Gesheff TB; Tantry US
J Am Coll Cardiol; 2009 Feb; 53(8):648-57. PubMed ID: 19232896
[TBL] [Abstract][Full Text] [Related]
2. Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study.
Gurbel PA; Bliden KP; Zaman KA; Yoho JA; Hayes KM; Tantry US
Circulation; 2005 Mar; 111(9):1153-9. PubMed ID: 15738352
[TBL] [Abstract][Full Text] [Related]
3. Influence of timing of clopidogrel treatment on the efficacy and safety of bivalirudin in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention: an analysis of the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.
Lincoff AM; Steinhubl SR; Manoukian SV; Chew D; Pollack CV; Feit F; Ware JH; Bertrand ME; Ohman EM; Desmet W; Cox DA; Mehran R; Stone GW;
JACC Cardiovasc Interv; 2008 Dec; 1(6):639-48. PubMed ID: 19463378
[TBL] [Abstract][Full Text] [Related]
4. Impact of bivalirudin or unfractionated heparin on platelet aggregation in patients pretreated with 600 mg clopidogrel undergoing elective percutaneous coronary intervention.
Sibbing D; Busch G; Braun S; Jawansky S; Schömig A; Kastrati A; Ott I; von Beckerath N
Eur Heart J; 2008 Jun; 29(12):1504-9. PubMed ID: 18467322
[TBL] [Abstract][Full Text] [Related]
5. The effects of aspirin and clopidogrel response on myonecrosis after percutaneous coronary intervention: a BRIEF-PCI (Brief Infusion of Intravenous Eptifibatide Following Successful Percutaneous Coronary Intervention) trial substudy.
Saw J; Densem C; Walsh S; Jokhi P; Starovoytov A; Fox R; Wong G; Buller C; Ricci D; Mancini GB; Fung A
JACC Cardiovasc Interv; 2008 Dec; 1(6):654-9. PubMed ID: 19463380
[TBL] [Abstract][Full Text] [Related]
6. Platelet function and coagulation in patients with STEMI and peri-interventional clopidogrel plus heparin vs. prasugrel plus bivalirudin therapy (BRAVE 4 substudy).
Braun D; Knipper A; Orban M; Sibbing D; Petzold T; Braun S; Schulz S; Hausleiter J; Kastrati A; Mehilli J; Massberg S
Thromb Res; 2016 Jan; 137():72-78. PubMed ID: 26639204
[TBL] [Abstract][Full Text] [Related]
7. Effect of clopidogrel with and without eptifibatide on tumor necrosis factor-alpha and C-reactive protein release after elective stenting: results from the CLEAR PLATELETS 1b study.
Gurbel PA; Bliden KP; Tantry US
J Am Coll Cardiol; 2006 Dec; 48(11):2186-91. PubMed ID: 17161243
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of a high on-clopidogrel treatment platelet reactivity in bivalirudin versus abciximab treated non-ST-segment elevation myocardial infarction patients. ISAR-REACT 4 (Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment-4) platelet substudy.
Sibbing D; Bernlochner I; Schulz S; Massberg S; Schömig A; Mehilli J; Kastrati A
J Am Coll Cardiol; 2012 Jul; 60(5):369-77. PubMed ID: 22682553
[TBL] [Abstract][Full Text] [Related]
9. Delayed thrombin-induced platelet-fibrin clot generation by clopidogrel: a new dose-related effect demonstrated by thrombelastography in patients undergoing coronary artery stenting.
Gurbel PA; Bliden KP; Guyer K; Aggarwal N; Tantry US
Thromb Res; 2007; 119(5):563-70. PubMed ID: 16806409
[TBL] [Abstract][Full Text] [Related]
10. Frequency and outcomes of provisional glycoprotein IIb/IIIa blockade in patients receiving bivalirudin during percutaneous coronary intervention.
Feldman DN; Wong SC; Bergman G; Minutello RM
J Invasive Cardiol; 2009 Jun; 21(6):258-63. PubMed ID: 19494400
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of a prolonged bivalirudin infusion after urgent and complex percutaneous coronary interventions: a descriptive study.
Cortese B; Micheli A; Picchi A; Bandinelli L; Brizi MG; Severi S; Limbruno U
Coron Artery Dis; 2009 Aug; 20(5):348-53. PubMed ID: 19543084
[TBL] [Abstract][Full Text] [Related]
12. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate?
Bliden KP; DiChiara J; Tantry US; Bassi AK; Chaganti SK; Gurbel PA
J Am Coll Cardiol; 2007 Feb; 49(6):657-66. PubMed ID: 17291930
[TBL] [Abstract][Full Text] [Related]
13. Comparison of platelet function and morphology in patients undergoing percutaneous coronary intervention receiving bivalirudin versus unfractionated heparin versus clopidogrel pretreatment and bivalirudin.
Anand SX; Kim MC; Kamran M; Sharma SK; Kini AS; Fareed J; Hoppensteadt DA; Carbon F; Cavusoglu E; Varon D; Viles-Gonzalez JF; Badimon JJ; Marmur JD
Am J Cardiol; 2007 Aug; 100(3):417-24. PubMed ID: 17659921
[TBL] [Abstract][Full Text] [Related]
14. The in vitro effect of eptifibatide, a glycoprotein IIb/IIIa antagonist, on various responses of porcine blood platelets.
Ciborowski M; Tomasiak M
Acta Pol Pharm; 2009; 66(3):235-42. PubMed ID: 19645323
[TBL] [Abstract][Full Text] [Related]
15. Prasugrel plus bivalirudin vs. clopidogrel plus heparin in patients with ST-segment elevation myocardial infarction.
Schulz S; Richardt G; Laugwitz KL; Morath T; Neudecker J; Hoppmann P; Mehran R; Gershlick AH; Tölg R; Anette Fiedler K; Abdel-Wahab M; Kufner S; Schneider S; Schunkert H; Ibrahim T; Mehilli J; Kastrati A;
Eur Heart J; 2014 Sep; 35(34):2285-94. PubMed ID: 24816809
[TBL] [Abstract][Full Text] [Related]
16. Lack of clopidogrel pretreatment effect on the relative efficacy of bivalirudin with provisional glycoprotein IIb/IIIa blockade compared to heparin with routine glycoprotein IIb/IIIa blockade: a REPLACE-2 substudy.
Saw J; Lincoff AM; DeSmet W; Betriu A; Rutsch W; Wilcox RG; Kleiman NS; Wolski K; Topol EJ;
J Am Coll Cardiol; 2004 Sep; 44(6):1194-9. PubMed ID: 15364319
[TBL] [Abstract][Full Text] [Related]
17. Increased expression of platelet P-selectin and formation of platelet-leukocyte aggregates in blood from patients treated with unfractionated heparin plus eptifibatide compared with bivalirudin.
Keating FK; Dauerman HL; Whitaker DA; Sobel BE; Schneider DJ
Thromb Res; 2006; 118(3):361-9. PubMed ID: 16139336
[TBL] [Abstract][Full Text] [Related]
18. High on clopidogrel treatment platelet reactivity is frequent in acute and rare in elective stenting and can be functionally overcome by switch of therapy.
Leé S; Vargová K; Hizoh I; Horváth Z; Gulácsi-Bárdos P; Sztupinszki Z; Apró A; Kovács A; Préda I; Tóth-Zsámboki E; Kiss RG
Thromb Res; 2014 Feb; 133(2):257-64. PubMed ID: 24359966
[TBL] [Abstract][Full Text] [Related]
19. Lack of early augmentation of platelet reactivity after coronary intervention in patients treated with bivalirudin.
Schneider DJ; Sobel BE
J Thromb Thrombolysis; 2009 Jul; 28(1):6-9. PubMed ID: 18607689
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of platelet aggregation with eptifibatide, bivalirudin, and heparin in patients undergoing percutaneous coronary intervention receiving clopidogrel pretreatment (The PharmacoDynamic Evaluation of Angiomax, Clopidogrel with or without INtegrilin [DEACON] study).
Saucedo JF; Aude W; Pacheco R; Thorn B; Matin Z; Husain K; Garza L
Am J Cardiol; 2005 Jun; 95(12):1453-6. PubMed ID: 15950569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
